A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
Latest Information Update: 15 Mar 2024
Price :
$35 *
At a glance
- Drugs INCB 106385 (Primary) ; Retifanlimab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 06 Mar 2024 Status changed from active, no longer recruiting to completed.
- 07 Jun 2023 Planned End Date changed from 29 Dec 2023 to 30 Jan 2024.
- 07 Jun 2023 Planned primary completion date changed from 29 Dec 2023 to 30 Jan 2024.